Clinical efficacy of bevacizumab in combination with FOLFOX4 regimen in the treatment of advanced colorectal cancer

Abstract

Objective To explore the efficacy and safety of advanced colorectal cancer patients treated by bevacizumab in combination with FOLFOX4 regimen. Methods Eighty-seven patients with advanced colorectal cancer were divided into bevacizumab combined with FOLFOX4 regimen group (the study group, 42 cases) and FOLFOX4 regimen only group (the control group, 45 cases) according to the treatment program. The efficacy, side effects and survival time in two groups were observed and compared. Results The response rate (RR) of the study and control group was 40.5% and 17.8%, respectively, and the disease control rate (DCR) of the two groups was 71.4% and 44.4%, respectively; both differences were statistically significant (P<0.05). The median disease free survival (DFS) of study group and control group was 8.9 and 5.8 months, respectively; the median overall survival (OS) of the two groups was 15.6 and 10.6 months, respectively; the differences were statistically significant (P<0.05). The side effects in two groups included diarrhea and gastrointestinal reactions, but all were grade Ⅰ-Ⅱ. Conclusion The efficacy of bevacizumab combined with FOLFOX4 regimen is reliable in treating patients with advanced colorectal cancer. It can increase the response rate and prolong median overall survival with low side effects. Key words: Bevacizumab; FOLFOX4; Advanced colorectal cancer